Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature
- PMID: 17123150
- DOI: 10.1007/s10549-006-9444-0
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature
Abstract
Paraneoplastic neurological syndromes are a rare complication of breast cancer. Nevertheless, they may be clinically relevant leading to neurological impairment. Clinicians should be aware that these neurological disorders could even precede the diagnosis of breast cancer. Here we present the case of a female patient with advanced breast cancer who developed paraneoplastic sensorimotor neuropathy. Treatment with capecitabine lead to clinical amelioration. A review of the literature on the paraneoplastic neurological syndromes in breast cancer is also included.
Similar articles
-
Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.Cancer Chemother Pharmacol. 2009 Apr;63(5):779-82. doi: 10.1007/s00280-008-0799-2. Epub 2008 Jul 19. Cancer Chemother Pharmacol. 2009. PMID: 18641989
-
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.Cancer Chemother Pharmacol. 2009 Apr;63(5):865-71. doi: 10.1007/s00280-008-0806-7. Epub 2008 Aug 1. Cancer Chemother Pharmacol. 2009. PMID: 18670777
-
Pharmacokinetic evaluation of capecitabine in breast cancer.Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):225-35. doi: 10.1517/17425255.2013.759939. Epub 2013 Jan 10. Expert Opin Drug Metab Toxicol. 2013. PMID: 23301520 Review.
-
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. doi: 10.1007/s00280-007-0650-1. Epub 2007 Dec 6. Cancer Chemother Pharmacol. 2008. PMID: 18071704 Clinical Trial.
-
Capecitabine in breast cancer: current status.Clin Breast Cancer. 2001 Jan;1(4):288-93; discussion 294. doi: 10.3816/CBC.2001.n.003. Clin Breast Cancer. 2001. PMID: 11899351 Review.
Cited by
-
Atypical Presentation of Carcinoma Breast as Paraneoplastic Cerebellar Degeneration on [18F]FDG PET/CT.Indian J Nucl Med. 2024 Jul-Aug;39(4):325-326. doi: 10.4103/ijnm.ijnm_35_24. Epub 2024 Nov 18. Indian J Nucl Med. 2024. PMID: 39790830 Free PMC article.
-
Severe polymyositis occurring in a cancer patient directly after chemotherapy: etiology and management.Future Sci OA. 2021 Jun 30;7(5):FSO706. doi: 10.2144/fsoa-2021-0011. Future Sci OA. 2021. PMID: 34211735 Free PMC article.
-
Paraneoplastic neurological complications of breast cancer.Exp Hematol Oncol. 2016 Oct 24;5:29. doi: 10.1186/s40164-016-0058-x. eCollection 2015. Exp Hematol Oncol. 2016. PMID: 27800287 Free PMC article. Review.
-
Paraneoplastic polymyositis presenting as a clinically occult breast cancer.Ann R Coll Surg Engl. 2017 Feb;99(2):e40-e43. doi: 10.1308/rcsann.2016.0301. Epub 2016 Sep 23. Ann R Coll Surg Engl. 2017. PMID: 27659377 Free PMC article.
-
Guillain-Barré Syndrome as a Presenting Symptom in Breast Cancer: The Importance of Considering Paraneoplastic Neurologic Syndrome.Cureus. 2021 Sep 13;13(9):e17932. doi: 10.7759/cureus.17932. eCollection 2021 Sep. Cureus. 2021. PMID: 34532200 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical